文献速递肝病

肝硬化患者骨质疏松筛查率低且患病率高:一项真实世界回顾性分析

Low screening rates and high prevalence of osteoporosis in cirrhosis: A real-world retrospective analysis.
PubMed 文献 · Aliment Pharmacol Ther · 2023-12-07

本研究对单一医疗系统6年内5398例肝硬化门诊患者进行回顾性病历审查,评估骨质疏松筛查、管理及不良药物事件。结果显示仅23.5%患者被开具DEXA检查,约50%完成检查;DEXA结果中48.5%有骨量减少、30.2%有骨质疏松,但仅22.6%的骨质疏松患者接受治疗,口服双膦酸盐处方与静脉曲张出血无关联。

要点

  • 肝硬化患者中仅23.5%被开具DEXA检查,约半数完成。
  • DEXA显示48.5%骨量减少、30.2%骨质疏松。
  • 仅22.6%骨质疏松患者接受治疗,口服双膦酸盐与静脉曲张出血无关联。

核心结论

  • 少数肝硬化患者接受了骨质疏松筛查;筛查者中多数存在骨量减少或骨质疏松;不足四分之一骨质疏松患者开始治疗;真实世界口服双膦酸盐使用未显示更高的胃肠道出血率;肝硬化骨健康管理各方面均有改进空间。

研究设计与样本

  • 回顾性病历审查,纳入单一医疗系统6年内就诊的成人代偿期和失代偿期肝硬化门诊患者,共5398例符合标准。

主要发现

  • 队列以白人为主(79.1%),年龄59岁,女性占44.4%,64.6%为失代偿期肝硬化,MELD-Na评分中位数12.8。
  • 23.5%患者被开具DEXA检查,约50%完成该检查。
  • DEXA扫描显示48.5%患者有骨量减少,30.2%有骨质疏松。
  • 仅22.6%骨质疏松患者接受治疗,最常用口服双膦酸盐。
  • 口服双膦酸盐处方与静脉曲张出血无关联(无处方者8.4% vs 有处方者4.8%,p=0.487)。

关键数值与推荐

  • 年龄较大、女性、白人、肝病更严重及有其他骨质疏松危险因素的患者更可能被开具DEXA检查。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cirrhosis are at increased risk for osteoporosis, and those who suffer a fracture are at high risk for mortality. Despite this, osteoporosis is often overlooked and undertreated. This study aimed to evaluate osteoporosis screening, management, and adverse osteoporosis medication events in patients with cirrhosis. METHODS: We performed a retrospective chart review of adult outpatients with compensated and decompensated cirrhosis seen in single health system over a 6-year period. Patient demographics, liver and bone health comorbidities, DEXA scan results, and medications were abstracted. RESULTS: In total, 5398 patients met criteria. The cohort was predominately white (79.1%) and older (age 59). 44.4% were female. 64.6% had decompensated cirrhosis. Median MELD-Na score was 12.8. 23.5% had a DEXA scan ordered, approximately 50% completed this test. Patients who were older, female, white, with more severe liver disease, and other osteoporosis risk factors were more likely to have a DEXA scan ordered. 48.5% of patients had osteopenia and 30.2% had osteoporosis on DEXA scan. Only 22.6% of patients with osteoporosis received treatment, most commonly oral bisphosphonates. Oral bisphosphonate prescription was not associated with variceal bleeding (8.4% without vs. 4.8% with, p = 0.487). CONCLUSION: A minority of patients with cirrhosis were screened for osteoporosis. The majority screened had osteopenia or osteoporosis on DEXA scan. Less than a quarter of patients with osteoporosis were started on treatment. Real-world experience of oral bisphosphonate use did not reveal higher rates of gastrointestinal bleeding. There is room for improvement in all aspects of bone health care in cirrhosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Thomson M, Scott A, Trost S, et al. Low screening rates and high prevalence of osteoporosis in cirrhosis: A real-world retrospective analysis. Aliment Pharmacol Ther. 2023. PMID: 38059360. doi:10.1111/apt.17823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。